{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:29:36Z","timestamp":1787502576445,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":1005,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1111\/jth.14457","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T12:30:56Z","timestamp":1556022656000},"page":"1064-1072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants"],"prefix":"10.1016","volume":"17","author":[{"given":"Sophie","family":"Testa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Legnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Dellanoce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benilde","family":"Cosmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Morandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Tripodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gualtiero","family":"Palareti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14457_bb0010","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.14457_bb0015","unstructured":"(FDA) FaDA. Pradaxa \u2010 clinical pharmacology and biopharmaceutics review(s). 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022512Orig1s000ClinPharmR_Corrrected%203.11.2011.pdf (accessed 17 January 2019). https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/nda\/2010\/022512Orig1s000ClinPharmR_Corrrected%203112011pdf. 2010."},{"key":"10.1111\/jth.14457_bb0020","unstructured":"(FDA) FaDA. Xarelto \u2010 clinical biopharmaceutics review(s). 2011. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022406Orig1s000ClinPharmR.pdf (accessed 26 September 2017). 2011."},{"key":"10.1111\/jth.14457_bb0025","unstructured":"(FDA) FaDA. Eliquis \u2010 clinical pharmacology and biopharmaceutics review(s). 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202155Orig1s000ClinPharmR.pdf Accessed 26 September 2017."},{"key":"10.1111\/jth.14457_bb0030","unstructured":"(EMA) EMA. Pradaxa \u2010 summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf. Accessed 26 September 2017."},{"key":"10.1111\/jth.14457_bb0035","unstructured":"(EMA) EMA. Xarelto \u2010 Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf. Accessed 26 September 2017."},{"key":"10.1111\/jth.14457_bb0040","unstructured":"(EMA) EMA. Eliquis \u2010 Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf. Accessed 26 September 2017."},{"key":"10.1111\/jth.14457_bb0045","unstructured":"(EMA) EMA. Lixiana \u2010 summary of product characteristics. European Medicines Agency. Lixiana \u2010 summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002629\/WC500189045.pdf. Accessed 26 September 2017."},{"key":"10.1111\/jth.14457_bb0050","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.thromres.2015.12.001","article-title":"Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics","volume":"137","author":"Testa","year":"2016","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14457_bb0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14457_bb0060","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMe1506600","article-title":"Targeted anti\u2010anticoagulants","volume":"373","author":"Bauer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14457_bb0065","doi-asserted-by":"crossref","first-page":"e0124719","DOI":"10.1371\/journal.pone.0124719","article-title":"The Italian START\u2010Register on anticoagulation with focus on atrial fibrillation","volume":"10","author":"Antonucci","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1111\/jth.14457_bb0070","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high\u2010risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14457_bb0075","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non\u2010surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14457_bb0080","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non\u2010major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non\u2010surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14457_bb0085","doi-asserted-by":"crossref","first-page":"345138","DOI":"10.1155\/2015\/345138","article-title":"Non\u2010VKA oral anticoagulants: accurate measurement of plasma drug concentrations","volume":"2015","author":"Douxfils","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1111\/jth.14457_bb0090","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14457_bb0095","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1160\/TH10-03-0204","article-title":"An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma","volume":"104","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14457_bb0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1111\/jth.14457_bb0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/jth.12227","article-title":"The role of the laboratory in treatment with new oral anticoagulants","volume":"11","author":"Baglin","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14457_bb0110","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/jth.13344","article-title":"To measure or not to measure direct oral anticoagulants before surgery or invasive procedures","volume":"14","author":"Tripodi","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14457_bb0115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14457_bb0120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.20452\/pamw.4287","article-title":"How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues.","volume":"128","author":"Tripodi","year":"2018","journal-title":"Pol Arch Intern Med"},{"key":"10.1111\/jth.14457_bb0125","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer\u2010Westendorf","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.14457_bb0130","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jama.2015.59","article-title":"Are new oral anticoagulant dosing recommendations optimal for all patients?","volume":"313","author":"Powell","year":"2015","journal-title":"JAMA"},{"key":"10.1111\/jth.14457_bb0135","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception\u2010 cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/jth.14457_bb0140","doi-asserted-by":"crossref","first-page":"e020212","DOI":"10.1136\/bmjopen-2017-020212","article-title":"Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study","volume":"8","author":"P","year":"2018","journal-title":"BMJ Open"},{"key":"10.1111\/jth.14457_bb0145","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.2015.2761","article-title":"Site\u2010level variation in and practices associated with dabigatran adherence","volume":"313","author":"Shore","year":"2015","journal-title":"JAMA"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14457","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14457","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622143606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622143606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:15:34Z","timestamp":1761534934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622143606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1538783622143606"],"URL":"https:\/\/doi.org\/10.1111\/jth.14457","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 The Authors. Journal of Thrombosis and Haemostasis. Published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}